Ten63 opens BEYOND-Alpha to a select group of drugmakers, with Chugai first to nominate hard targets
Ten63 Therapeutics launched BEYOND-Alpha on November 18, 2026, an early adopter program in which a limited number of pharmaceutical companies work with Ten63 to apply its BEYOND computational drug design platform to challenging targets. Chugai Pharmaceutical is the first participant: it nominates targets, Ten63 generates and ranks molecular structures against each one, and Chugai holds the right to negotiate terms for further research, development and commercialization, subject to a separate definitive agreement. The program is designed to let Ten63's computational design infrastructure run across multiple drug discovery programs in parallel.